Verona Pharma plc (VRNA)
Largest Insider Buys in Sector
VRNA Stock Price History Chart
VRNA Stock Performance
About Verona Pharma plc
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing …
Insider Activity of Verona Pharma plc
Over the last 12 months, insiders at Verona Pharma plc have bought $641,359 and sold $14.26M worth of Verona Pharma plc stock.
On average, over the past 5 years, insiders at Verona Pharma plc have bought $2.42M and sold $80.27M worth of stock each year.
Highest buying activity among insiders over the last 12 months: ACKERMANN CHRISTINA (director) — $396,771. EBSWORTH DAVID R (director) — $381,001. Edwards Martin (director) — $61,973.
The last purchase of 20,000 shares for transaction amount of $88,800 was made by EBSWORTH DAVID R (director) on 2024‑11‑18.
List of Insider Buy and Sell Transactions, Verona Pharma plc
| 2024-11-18 | director | 20,000 0.0031% | $4.44 | $88,800 | +686.94% | |||
| 2024-11-11 | Sale | President and CEO | 2,400 0.0004% | $5.00 | $12,000 | -7.37% | ||
| 2024-11-11 | Sale | Chief Financial Officer | 2,400 0.0004% | $5.00 | $12,000 | -7.37% | ||
| 2024-11-06 | director | 39,360 0.0062% | $4.80 | $188,881 | +2.10% | |||
| 2024-11-06 | director | 41,880 0.0065% | $4.74 | $198,386 | +2.10% | |||
| 2024-11-04 | Sale | President and CEO | 94,144 0.0131% | $4.39 | $413,462 | +0.08% | ||
| 2024-11-04 | Sale | Chief Financial Officer | 80,784 0.0112% | $4.39 | $354,448 | +0.08% | ||
| 2024-11-01 | Sale | President and CEO | 46,888 0.0072% | $4.38 | $205,196 | +9.11% | ||
| 2024-11-01 | Sale | Chief Financial Officer | 48,888 0.0075% | $4.38 | $213,939 | +9.11% | ||
| 2024-10-25 | Sale | President and CEO | 4,800 0.0007% | $4.38 | $21,004 | 0.00% | ||
| 2024-10-25 | Sale | Chief Financial Officer | 3,200 0.0005% | $4.38 | $14,000 | 0.00% | ||
| 2024-10-24 | Sale | President and CEO | 140,000 0.0217% | $4.38 | $612,822 | 0.00% | ||
| 2024-10-24 | Sale | Chief Financial Officer | 141,360 0.0219% | $4.38 | $618,761 | 0.00% | ||
| 2024-10-23 | Sale | President and CEO | 16 <0.0001% | $4.38 | $70 | 0.00% | ||
| 2024-10-22 | Sale | President and CEO | 157,912 0.0245% | $4.39 | $692,728 | 0.00% | ||
| 2024-10-22 | Sale | Chief Financial Officer | 159,344 0.0247% | $4.38 | $698,708 | 0.00% | ||
| 2024-10-21 | Sale | President and CEO | 110,456 0.0171% | $4.38 | $483,753 | +6.55% | ||
| 2024-10-21 | Sale | Chief Financial Officer | 116,696 0.018% | $4.38 | $511,082 | +6.55% | ||
| 2024-10-18 | Sale | President and CEO | 245,784 0.0383% | $4.38 | $1.08M | +6.64% | ||
| 2024-10-18 | Sale | Chief Financial Officer | 249,728 0.039% | $4.38 | $1.09M | +6.64% |
Insider Historical Profitability
| EBSWORTH DAVID R | director | 940003 1.1487% | $39.22 | 4 | 2 | |
| Edwards Martin | director | 144800 0.1769% | $39.22 | 1 | 2 | |
| ACKERMANN CHRISTINA | director | 41880 0.0512% | $39.22 | 1 | 0 | |
| Blavatnik Len | 55911648 68.3256% | $39.22 | 1 | 0 | +61.86% |
Institutional Investor Ownership
| RA Capital Management, L.P. | $101.66M | 62.34 | 6.32M | 0% | +$0 | 0.1 | |
| Nea Management Company Llc | $89.86M | 50.4 | 5.11M | 0% | +$0 | 0.42 | |
| Wellington Management Company | $62.9M | 38.57 | 3.91M | +3.32% | +$2.02M | 0.01 | |
| Perceptive Advisors | $60.52M | 37.11 | 3.76M | -2.71% | -$1.68M | 0.04 | |
| Vivo Capital | $58.09M | 35.62 | 3.61M | -15.05% | -$10.29M | 5.06 |